CEL-SCI (CVM) announced new data has been published from its prior Phase 3 study of Multikine in newly diagnosed, treatment naive, resectable, ...

During a live event, Sumanta K. Pal, MD, discusses the efficacy and safety findings from the CheckMate 274 trial of adjuvant ...

Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.

A recent study published in JAMA Oncology presents promising new data on a treatment regimen beneficial to patients with a ...

The study randomly assigned 42 patients (one would later withdraw consent) to three immunotherapy treatment arms: nivolumab ...

Patients who received semaglutide before MBS from 2017 to 2024 were matched 1:1 with patients who did not receive semaglutide before MBS using nearest-neighbor propensity score matching.

Use of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among patients with early triple-negative breast cancer (TNBC), but a 12-week ...